{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 48,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/33",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.44,
        "x": 0.517,
        "y": 0.35
      },
      "kind": "callout",
      "text": "There was a greater percentage of high responder patients treated with OCS-02 compared to vehicle at Day 29 (P = 0.018)",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "919b7bb5-fb65-4589-959e-b05f54e8ba6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.62,
        "w": 0.44,
        "x": 0.048,
        "y": 0.202
      },
      "kind": "chart",
      "text": "HIGH RESPONDER RATE\nP = 0.018\n17.9%\n4.7%\n% Patients with >20+ points improvement\nOCS-02 (N=67)\nVehicle (N=64)",
      "attrs": {
        "chart_type": "bar",
        "data_points": [
          {
            "x": "OCS-02",
            "y": 17.9
          },
          {
            "x": "Vehicle",
            "y": 4.7
          }
        ],
        "series_names": [
          "OCS-02",
          "Vehicle"
        ],
        "x_axis_label": "Treatment Group",
        "y_axis_label": "% Patients with >20+ points improvement"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03e6402b-6e1b-4929-9259-8734be1ae6d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.16,
        "x": 0.059,
        "y": 0.863
      },
      "kind": "other",
      "text": "Per protocol population",
      "attrs": {},
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23e3f403-6959-43cb-b257-32038dc2447f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.44,
        "x": 0.517,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "High responding patients is defined as patients who improve in global ocular discomfort score* by >20 points",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35be03fe-4b61-4bd9-8f5a-770e2c09cb59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.026,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "* Change from baseline in global ocular discomfort score based on the Symptom Assessment iN Dry Eye (SANDE) questionnaire. Shettle L, et al. Clin. Ophthalmol. 2022;16:2167-2177.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b199e791-1dce-488b-b097-0fa10ba63c8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.73,
        "x": 0.026,
        "y": 0.04
      },
      "kind": "title",
      "text": "OCS-02 (Licaminlimab) Phase 2a: Treated Group Had Clinically Meaningful Results",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ccda557-f1b8-4773-976b-57b133015cc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.026,
        "y": 0.118
      },
      "kind": "title",
      "text": "Secondary endpoint – Percentage of high responder patients at Day 29",
      "attrs": {},
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed85f4f-a009-4978-b585-92533ecf304e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "6a6d6664-ef14-4cc0-9a01-8689aa36bea8",
      "evidence": "chart/bar-vertical: HIGH RESPONDER RATE P = 0.018 17.9% 4.7% % Patients with >20+ points improvement OCS-02 (N=67) Vehicle (N=64)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}